Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT00419783
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)
- Conditions
- Interventions
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2013-07-17
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00414011
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Therapeutic Variables in Cataract Surgery
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- Innovative Medical
- Registration Number
- NCT00407017
- Locations
- 🇺🇸
The Center for Excellence in Eye Care, Miami, Florida, United States
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 66
- Registration Number
- NCT00398411
- Locations
- 🇩🇪
Klinikum der Universität zu Köln, Köln, Germany
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 70
- Registration Number
- NCT00396084
- Locations
- 🇺🇸
San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States
🇧🇷Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
A Study of the Electrocardiogram Effects and Pharmacokinetics of Ferumoxytol in Healthy Men and Women
- Conditions
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AMAG Pharmaceuticals, Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT00360425
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
- First Posted Date
- 2006-04-10
- Last Posted Date
- 2012-11-02
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 137
- Registration Number
- NCT00312338
- Locations
- 🇺🇸
Multiple Locations, Fort Worth, Texas, United States
Pharmacokinetic Interaction Study in Indonesian Tuberculosis Patients Indonesia
- Conditions
- First Posted Date
- 2006-03-23
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00306319
- Locations
- 🇮🇩
Rumah Sakit Hasan Sadikin (RSHS), Bandung, Indonesia
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
- Conditions
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 398
- Registration Number
- NCT00254566
- Locations
- 🇹🇭
Pfizer Investigational Site, Khon Kaen, Thailand
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2005-12-15
- Lead Sponsor
- J. Uriach and Company
- Target Recruit Count
- 160
- Registration Number
- NCT00199225
- Locations
- 🇪🇸
Centre de Investigació de Medicaments-Intitut de Recerca-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.